Overview

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this first-in-man study is to investigate whether a new drug for neurological disorders is safe and well-tolerated when administered orally to healthy male adults
Phase:
Phase 1
Details
Lead Sponsor:
Actelion
Idorsia Pharmaceuticals Ltd.